Answers are grounded in this paper and cite their sources.
Carbapenemase-producing Gram-negative bacteria are among the most challenging pathogens encountered in contemporary infectious diseases and critical care practice. Although antimicrobial susceptibility testing remains the cornerstone of laboratory diagnosis, reliance on the minimum inhibitory concentration (MIC) in isolation is insufficient to predict clinical outcome. The activity of a given regimen is governed by an interplay of factors that extends well beyond the static, in vitro MIC value: the specific carbapenemase produced (Ambler class A, B or D), co-existing resistance determinants such as porin loss, efflux-pump over-expression and AmpC hyperproduction, the infecting species and its intrinsic resistome, the anatomical site of infection and the antibiotic exposure actually achievable there, and the markedly altered pharmacokinetics of critically ill patients. This narrative review synthesizes recent evidence, with an emphasis on literature published between 2021 and 2026, on the molecular epidemiology of carbapenemases; the mechanism-specific activity of novel beta-lactam/beta-lactamase-inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, aztreonam-avibactam, cefepime-taniborbactam, and cefepime-enmetazobactam); cefiderocol; sulbactam-durlobactam; and legacy agents, alongside species-specific resistance patterns in Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Particular attention is paid to tissue and cerebrospinal fluid penetration and to pharmacokinetic/pharmacodynamic optimization strategies-including extended and continuous infusion, correction for augmented renal clearance and hypoalbuminemia, and therapeutic drug monitoring-that are essential in the critically ill. We propose ROAD, a practical four-step educational checklist that organizes established, mechanism-guided prescribing principles (Resolve the resistance mechanism, Organism and actual susceptibility, Anatomical site and source control, Dose, delivery and dynamic review), and provide summative tables mapping carbapenemase class to guideline-based agents and antibiotic exposure across key infection sites. ROAD is intended for carbapenem-resistant Gram-negative infection in which carbapenemase production is suspected or must be excluded; non-carbapenemase mechanisms are considered as differential diagnoses within the checklist. ROAD has not been prospectively validated; its effect on prescribing and clinical outcomes requires prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: